mohd izzuan
TG Therapeutics (NASDAQ:TGTX) shares lost ~18% on Monday after the Morrisville, North Carolina-based biotech fell short of expectations with its Q2 2025 financials but raised its full-year sales outlook to a level below consensus.
TG (NASDAQ:TGTX) reported $141.2M in net